Genialis

Genialis, operating under the motto "Know your patient, know your drug," is a pioneering figure in the field of precision oncology. Founded in 2015, this United States-based company is at the forefront of transforming healthcare by developing and validating clinically actionable biomarkers.

By leveraging one of the world's most ethnographically diverse cancer data sets, Genialis is significantly enhancing the predictability of patient responses to various treatment modalities, including targeted inhibitors and immunotherapies. Their approach not only informs better treatment decisions but also aims for the best possible outcomes for patients and their communities.

The company's innovative solutions have earned them the trust of prominent pharmaceutical and diagnostics partners. Their recent funding success—a $13.00M Series A investment secured in March 2023—was backed by investors such as First Star Ventures, The Group Ventures, Redalpine, Pikas, and Taiwania Capital, underscoring investor confidence in their mission and potential for sustainable growth.